Known targets — ChEMBL curated mechanism
SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9A
The experimentally established mechanism targets of Indecainide. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.36 |
| ▸ | APEX1 | P27695 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Indecainide SCHEMBL11086669 | 0.99 | KDM4E (0.41) | KDM4EALDH1A1TDP1APEX1 | |
| Indecainide SCHEMBL29397898 | 0.99 | KDM4E (0.41) | KDM4EALDH1A1TDP1APEX1 | |
| Indecainide SCHEMBL121201 | 0.99 | KDM4E (0.41) | KDM4EALDH1A1TDP1APEX1 | |
| Indecainide SCHEMBL1649456 | 0.97 | KDM4E (0.41) | KDM4EALDH1A1TDP1APEX1 | |
| Indecainide SCHEMBL11078673 | 0.96 | KDM4E (0.43) | KDM4EALDH1A1TDP1APEX1 | |
| SCHEMBL11090876 | 0.85 | KDM4E (0.41) | KDM4EALDH1A1TDP1 | |
| SCHEMBL10995584 | 0.84 | APEX1 (0.40) | TDP1APEX1KMT2A | |
| Hydrochloric Acid SCHEMBL11090502 | 0.84 | KDM4E (0.41) | KDM4EALDH1A1TDP1PDK2 | |
| SCHEMBL11092008 | 0.84 | KDM4E (0.41) | KDM4EALDH1A1TDP1APEX1 | |
| SCHEMBL11091509 | 0.82 | ALDH1A1 (0.42) | KDM4EALDH1A1TDP1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 787 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025111482-A1 | COMPLEXING AGENT SALT FORMULATIONS OF PHARMACEUTICAL COMPOUNDS AT LOW STOICHIOMETRIC RATIOS | BEXSON BIOMEDICAL, INC. (US) | 2025-05-30 | — | — | WO | claimed |
| CN-119233997-A | Tetrahedral antibodies | 生物分子控股有限责任公司 | 2024-12-31 | — | — | CN | claimed |
| US-20240398819-A1 | UTILITY OF VITAMIN D, FOLIC ACID AND NADH TO IMPROVE LIGAMENT INJURY PREVENTION CHARACTERISTICS | RHODE ISLAND HOSPITAL | 2024-12-05 | — | — | US | claimed |
| EP-4463485-A2 | TETRAHEDRAL ANTIBODIES | Biomolecular Holdings LLC (US) | 2024-11-20 | — | — | EP | claimed |
| WO-2023137387-A2 | TETRAHEDRAL ANTIBODIES | BIOMOLECULAR HOLDINGS LLC (US) | 2023-07-20 | — | — | WO | claimed |
| WO-2023137373-A1 | TETRAHEDRAL ANTIBODIES | BIOMOLECULAR HOLDINGS LLC (US) | 2023-07-20 | — | — | WO | claimed |
| US-20230220115-A1 | TETRAHEDRAL ANTIBODIES | BIOMOLECULAR HOLDINGS LLC (US) | 2023-07-13 | — | — | US | claimed |
| US-20230220116-A1 | TETRAHEDRAL ANTIBODIES | BIOMOLECULAR HOLDINGS LLC (US) | 2023-07-13 | — | — | US | claimed |
| EP-4178615-A1 | TETRAHEDRAL ANTIBODIES | Biomolecular Holdings LLC (US) | 2023-05-17 | — | — | EP | claimed |
| US-11225490-B2 | Prodrugs of secondary amine compounds | ALKERMES PHARMA IRELAND LIMITED (IE) | 2022-01-18 | — | — | US | claimed |
| WO-2003018102-A2 | TOPICAL ADMINISTRATION DEVICE | VECTURA LIMITED (US) | 2003-03-06 | — | — | WO | claimed |
| US-20020115655-A1 | Such as S-(4-methoxybenzyl)-N-(2-(N',N'-dimethylamino)ethyl) thiosalicylamide; for treatment of cardiovascular disorders | MASSACHUSETTS COLLEGE OF PHARMACY | 2002-08-22 | — | — | US | claimed |
| EP-1073470-A1 | PHARMACEUTICAL COMPOSITIONS CONTAINING COMPOUNDS WITH ACTIVITY FOR THE ENHANCEMENT OF ABSORPTION OF ACTIVE INGREDIENTS | INPHARMA S.A. (CH) | 2001-02-07 | — | — | EP | claimed |
| WO-2000048636-A1 | PHARMACEUTICAL COMPOSITIONS CONTAINING COMPOUNDS WITH ACTIVITY FOR THE ENHANCEMENT OF ABSORPTION OF ACTIVE INGREDIENTS | INPHARMA S.A. (CH) | 2000-08-24 | — | — | WO | claimed |
| EP-0038676-B1 | PROCESS FOR PREPARING FLUORENE DERIVATIVES | ELI LILLY AND COMPANY (US) | 1984-10-17 | — | — | EP | claimed |
| US-4452745-A | ANTIARRHYTHMIA AGENTS | ELI LILLY AND COMPANY (US) | 1984-06-05 | — | — | US | claimed |
| EP-0018076-B1 | 9-AMINOALKYLFLUORENES, PROCESS THEREFOR AND ANTIARRHYTHMIC FORMULATIONS THEREOF | ELI LILLY AND COMPANY (US) | 1983-09-21 | — | — | EP | claimed |
| US-4382093-A | 9-Aminoalkylfluorenes | ELI LILLY AND COMPANY (US) | 1983-05-03 | — | — | US | claimed |
| EP-0038676-A1 | Process for preparing fluorene derivatives | ELI LILLY AND COMPANY (US) | 1981-10-28 | — | — | EP | claimed |
| EP-0018076-A1 | 9-Aminoalkylfluorenes, process therefor and antiarrhythmic formulations thereof | ELI LILLY AND COMPANY (US) | 1980-10-29 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230220115-A1 | TETRAHEDRAL ANTIBODIES | FCGR3B, FCGR2A, FCGR1A | KDM4E 4119/4885ALDH1A1 4781/4885TDP1 3593/4885 |
| US-20230220116-A1 | TETRAHEDRAL ANTIBODIES | FCGR3B, FCGR2A, FCGR1A | KDM4E 4119/4885ALDH1A1 4781/4885TDP1 3593/4885 |
| US-20020115655-A1 | Such as S-(4-methoxybenzyl)-N-(2-(N',N'-dimethylamino)ethyl) thiosalicylamide; for treatment of cardiovascular disorders | CACNA1G, CACNA1F, CACNA1H | KDM4E 1917/4885ALDH1A1 1804/4885TDP1 3665/4885 |
| US-11225490-B2 | Prodrugs of secondary amine compounds | HNMT, MAOB, UGT1A1 | KDM4E 2015/4885ALDH1A1 288/4885TDP1 741/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.